People living with lung cancer launch a social media takeover August 1
People living with lung cancer launch a social media takeover!
Los Angeles, CA, July 28, 2021 (GLOBE NEWSWIRE) -- Join dozens of patient advocates living with lung cancer and meet the researchers working to find better treatments for the disease...
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34295687/
In oncogene-addicted NSCLC (with the exception of KRAS -mutated), ICIs are usually administered at the failure of other treatment options, but administering single-agent immunotherapy in later disease phases may limit...
A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34293517/
doi: 10.1016/j.lungcan.2021.05.026. Online ahead of print. 1 Virginia Cancer Specialists, 8503 Arlington Blvd Suite 400, Fairfax, VA, 22031, USA; US Oncology Research, The Woodlands, TX, USA; Johns Hopkins School of...
Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34257540/
Comprehensive genomic profiling (CGP) and immunohistochemistry (IHC) are important biomarker tools used for patients with non-small cell lung cancer (NSCLC) given the expanding number of standard-of-care therapies that require companion...
Emerging Therapies Expand Options in Lung Cancer
Emerging Therapies Expand Options in Lung Cancer
Source : https://www.onclive.com/view/emerging-therapies-expand-options-in-lung-cancer
During the past 12 months, the treatment landscape for patients with non-small cell lung cancer has expanded dramatically with FDA approvals of the first drugs directed at KRAS G12C and...